BMB-101
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Absence Epilepsy
Conditions
Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome, Lennox Gastaut Syndrome
Trial Timeline
Dec 5, 2024 → Nov 30, 2025
NCT ID
NCT06401538About BMB-101
BMB-101 is a phase 2 stage product being developed by Bright Minds Biosciences for Absence Epilepsy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06401538. Target conditions include Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06401538 | Phase 2 | Recruiting |
Competing Products
9 competing products in Absence Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| topiramate | Johnson & Johnson | Phase 2 | 52 |
| Idelalisib | Gilead Sciences | Pre-clinical | 22 |
| rapamune, mycophenolate mofetil and steroid + tacrolimus, sirolimus and steroid | Pfizer | Pre-clinical | 22 |
| Brivaracetam Film-coated tablet + Brivaracetam oral solution | UCB | Phase 3 | 74 |
| Brivaracetam Film-coated tablet + Brivaracetam oral solution | UCB | Phase 3 | 74 |
| Levetiracetam | UCB | Phase 2 | 49 |
| Brivaracetam | UCB | Phase 3 | 74 |
| Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole | Jazz Pharmaceuticals | Phase 1 | 30 |
| Cannabidiol (Epidiolex) | Jazz Pharmaceuticals | Approved | 82 |